Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Gilead Sciences

The Saturday Spread: Data-Driven Trades That Cut Through the Noise (GILD, MCD, DJT)

This weekend’s edition identifies three hot stocks that are flashing above-average upside probabilities with compelling multi-leg options strategies.

Barchart

US approves twice-yearly injection for HIV prevention – what you need to know about lenacapavir

The US Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that offers long-lasting protection against HIV infection. Administered once every six months, this new treatment marks a major advancement in expanding prevention options for people at risk of HIV infection.

The Conversation

Marjorie Taylor Greene Buys Stocks Focusing on Tech, Energy, and a Biotech Firm That Recently Received FDA Approval for HIV Drug

US Congress member Marjorie Taylor Greene purchased shares of Adobe, Netflix, Snowflake, ServiceNow, NextEra Energy, and Gilead Sciences on 6th June.

International Business Times UK

From analysis to the latest developments in health,
read the most diverse news in one place.

US Approves Gilead's Twice-yearly Injection To Prevent HIV

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move the company hailed as a major breakthrough in the fight against the sexually transmitted virus.

International Business Times

Is Gilead Sciences Stock Outperforming the S&P 500?

While Gilead Sciences has outperformed the S&P 500 Index over the past year, analysts are cautiously optimistic about the stock’s prospects.

Barchart

Alzheimer's and cold sores: Are they linked?

Could cold sores be linked to an increased risk of developing dementia? Could cold sore treatment be used to treat Alzheimer’s?

Evening Standard

Unusual Options Alert: The Smart Money is Piling Into Gilead Sciences (GILD)

While the new political paradigm might not be the most conducive environment for Gilead Sciences, positive sentiment is brewing for GILD stock.

Barchart

Read news from The Economist, FT, and more,
with one subscription

3 Biotech Giants Gaining From U.S. Sales and Policy Shifts

The significant domestic revenue base of select US biotech companies offers stability potential for investors navigating global trade complexities.

MarketBeat

Prison needle programs could save double what they cost – our new modelling shows how

Needle and syringe programs are a proven public health intervention that provide free, sterile injecting equipment to people who use drugs. By reducing needle sharing, these programs help prevent the spread of blood-borne viruses such as hepatitis C and HIV and minimise life-threatening bacterial infections.

The Conversation

Here's What to Expect From Gilead Sciences’ Next Earnings Report

Gilead Sciences is expected to announce its fiscal first-quarter earnings this month, and analysts forecast a robust triple-digit in its earnings.

Barchart

These 2 Buy-Rated Dividend Stocks Could Be Next in Line for a Trump Tariff Selloff. Should You Jump Ship Now?

Trump’s proposed tariffs on pharmaceutical imports from countries like Ireland and India have sparked concerns for companies like Amgen and Gilead Sciences.

Barchart

Gilead Sciences - Leader in HIV Medicines

Summary Gilead Sciences (GILD) shows strong technical buy signals, with a 19.60% gain since Trend Seeker's buy signal on 1/27 and a 50.31% gain in the last year. The company offers a diverse portfolio of medicines for HIV, COVID-19, liver diseases, oncology, and more, with significant collaborations enhancing its pipeline....

Barchart

These 3 Dividend Stocks Jumped 15% in a Month—More to Come?

Dividend stocks aren't just for long-term income generation. These three shares have jumped 15% in one month while also offering dividend payouts.

MarketBeat

5 years since COVID was declared a pandemic, we’re still poorly prepared for the next one

On March 11 2020, as COVID continued to spread rapidly around the globe, the World Health Organization (WHO) officially declared a pandemic.

The Conversation

Get all your
news in one place.

100’s of premium titles.
One news app.

MarketBeat

Gilead Sciences: 4 Reasons This Stock Has Much More To Rise

Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summer

Barchart

Stocks Settle Mixed as Chip Stock Strength Lifts the Nasdaq

The S&P 500 Index ($SPX ) (SPY ) Wednesday closed down -0.27%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.50%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.12%. March E-mini S&P futures (ESH25 ) are down by -0.29%, and March E-mini Nasdaq...

Barchart

Stocks Tumble as Sticky US Inflation Keeps Fed on Hold

The S&P 500 Index ($SPX ) (SPY ) today is down -0.50%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.63%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.32%. March E-mini S&P futures (ESH25 ) are down by -0.48%, and March E-mini Nasdaq...

Barchart

Gilead Sciences Stock: Is Wall Street Bullish or Bearish?

Shares of Gilead Sciences have surpassed the broader market over the past year, and Wall Street analysts are reasonably upbeat about its future outlook.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?

Gilead Sciences has recently demonstrated strong performance, outperforming the broader healthcare sector, and analysts maintain a cautiously optimistic outlook on its future.

Benzinga

Looking At Gilead Sciences's Recent Unusual Options Activity

Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences (NASDAQ:GILD).

The Conversation

A new at-home test will soon be available for chlamydia and gonorrhoea. Here’s what to know

Australia’s Therapeutic Goods Administration (TGA) has recently approved a self-test kit for chlamydia and gonorrhoea for women and other people with a vagina.

The Conversation

Five things you should know about the HIV epidemic

It is 40 years since Aids was first identified. Major strides have been made since the spread of the virus reached epidemic proportions in 1995 when 3.3 million people were infected with HIV and just under one million people died.

StockNews.com

3 Biotech Stocks with Promising Pipelines to Watch

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

Barchart

Gilead Sciences Stock: Analyst Estimates & Ratings

Gilead Sciences has underperformed the broader market over the past year, but Wall Street analysts are moderately optimistic about the stock’s prospects.

Barchart

Option Volatility And Earnings Report For November 4 - 8

We have some important companies with Palantir, Super Micro computer, Block, Moderna, Qualcomm, Arista Networks, Gilead Sciences and Airbnb all set to report.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.